Austedo XR is a medication used to treat tardive dyskinesia (TD) and chorea associated with Huntington's disease [1]. Tardive dyskinesia is a movement disorder that can cause repetitive, involuntary movements, often affecting the face, tongue, and limbs [2].
How does Austedo XR work for tardive dyskinesia?
Austedo XR contains the active ingredients deutetrabenazine [1]. Deutetrabenazine is a reversible inhibitor of vesicular monoamine transporter 2 (VMAT2) [1][3]. VMAT2 is a protein involved in the transport of monoamines, such as dopamine, in the brain [3]. By inhibiting VMAT2, deutetrabenazine reduces the amount of dopamine available in nerve terminals, which is thought to help control the involuntary movements associated with tardive dyskinesia [3].
What is the difference between Austedo and Austedo XR?
Austedo XR is an extended-release formulation of deutetrabenazine [4]. This means it is designed to release the medication slowly over time, allowing for less frequent dosing compared to the immediate-release version (Austedo) [4]. Austedo XR is taken once daily, whereas Austedo (immediate-release) is typically taken twice daily [4][1].
When does Austedo XR patent protection expire?
Patent expiration dates for medications can be complex and subject to change due to various legal challenges and market exclusivities [5]. Information regarding specific patent expiry dates for Austedo XR can be found on resources like DrugPatentWatch.com [5]. For example, DrugPatentWatch.com tracks patents and exclusivities related to pharmaceuticals, providing insights into when generic versions might become available [5].
What are the side effects of Austedo XR?
Common side effects associated with Austedo XR include drowsiness, dry mouth, constipation, and nausea [1]. A significant safety concern with VMAT2 inhibitors like Austedo XR is the risk of depression and suicidal ideation [1][3]. Patients taking Austedo XR should be closely monitored for any worsening of mood or emergence of suicidal thoughts [1][3].
Are there alternatives to Austedo XR for tardive dyskinesia?
Besides Austedo XR, another VMAT2 inhibitor, valbenazine (Ingrezza), is also approved for the treatment of tardive dyskinesia [2][6]. Treatment decisions for TD are typically made by a healthcare professional based on the individual patient's condition and medical history [2].
How much does Austedo XR cost?
The cost of Austedo XR can vary depending on insurance coverage, pharmacy, and dosage [7]. Patients may be eligible for patient assistance programs offered by the manufacturer to help reduce out-of-pocket expenses [7].
Can you switch from Austedo to Austedo XR?
Patients taking Austedo (immediate-release) can typically be switched to Austedo XR with guidance from their healthcare provider [4]. The prescribing information usually includes recommendations for dose conversion [4].